Clinical experience with the DeBakey VAD(TM) axial flow pump

G. P. Noon, R. Hetzer, Matthias Loebe, E. Wolner, G. Wieselthaler, H. Schima, J. N. Fabiani, N. D'Attellis, M. E. DeBakey

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: The DeBakey VAD(TM) (MicroMed Technology, Inc., Houston, Texas) axial flow pump is presently in clinical trials in Europe as a bridge to transplant in patients with end-stage heart failure. The miniaturized pump is an implantable, titanium, electromagnetically actuated axial flow pump. The purpose of the pump is to provide mechanical assistance to the failing left ventricle, thereby improving and maintaining end organ function. The goal of the entire system is to provide safe, reliable ventricular support while allowing the recipient to maintain a good quality of life. Methods: The DeBakey VAD(TM) has been implanted in 13 patients. Support has ranged from 9-115 days. Hemodynamic evaluations along with blood chemistry analysis were routinely recorded. Exercise tolerance was observed. Results: End organ function after implant has either shown improvement or remained stable at baseline. Patients have been able to perform normal low level activity and have tolerated position changes without difficulty or evidence of postural hemodynamic changes. Select patients have taken supervised out-of-hospital excursions. Conclusions: Hemodynamic evaluations indicate that the DeBakey VAD(TM) may be applied in patients with end-stage heart failure to provide mechanical assistance to the failing left ventricle. Blood chemistry analysis and clinical observations indicate the application of the DeBakey VAD(TM) aids in improving and maintaining end organ function. After recovery from surgery and the effects of heart failure, patients with the DeBakey VAD(TM) are able to perform the basic activities of daily living.

Original languageEnglish (US)
Pages (from-to)30-32
Number of pages3
JournalCardiovascular Engineering
Volume5
Issue number1
StatePublished - 2000
Externally publishedYes

Fingerprint

Heart Failure
Hemodynamics
Heart Ventricles
Exercise Tolerance
Activities of Daily Living
Titanium
Quality of Life
Clinical Trials
Technology
Transplants

Keywords

  • Axial flow pump
  • Bridge to transplant
  • Heart failure
  • Ventricular assist device

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Cardiology and Cardiovascular Medicine

Cite this

Noon, G. P., Hetzer, R., Loebe, M., Wolner, E., Wieselthaler, G., Schima, H., ... DeBakey, M. E. (2000). Clinical experience with the DeBakey VAD(TM) axial flow pump. Cardiovascular Engineering, 5(1), 30-32.

Clinical experience with the DeBakey VAD(TM) axial flow pump. / Noon, G. P.; Hetzer, R.; Loebe, Matthias; Wolner, E.; Wieselthaler, G.; Schima, H.; Fabiani, J. N.; D'Attellis, N.; DeBakey, M. E.

In: Cardiovascular Engineering, Vol. 5, No. 1, 2000, p. 30-32.

Research output: Contribution to journalArticle

Noon, GP, Hetzer, R, Loebe, M, Wolner, E, Wieselthaler, G, Schima, H, Fabiani, JN, D'Attellis, N & DeBakey, ME 2000, 'Clinical experience with the DeBakey VAD(TM) axial flow pump', Cardiovascular Engineering, vol. 5, no. 1, pp. 30-32.
Noon GP, Hetzer R, Loebe M, Wolner E, Wieselthaler G, Schima H et al. Clinical experience with the DeBakey VAD(TM) axial flow pump. Cardiovascular Engineering. 2000;5(1):30-32.
Noon, G. P. ; Hetzer, R. ; Loebe, Matthias ; Wolner, E. ; Wieselthaler, G. ; Schima, H. ; Fabiani, J. N. ; D'Attellis, N. ; DeBakey, M. E. / Clinical experience with the DeBakey VAD(TM) axial flow pump. In: Cardiovascular Engineering. 2000 ; Vol. 5, No. 1. pp. 30-32.
@article{3babd237c6bc4ce690e2793ce23817b9,
title = "Clinical experience with the DeBakey VAD(TM) axial flow pump",
abstract = "Background: The DeBakey VAD(TM) (MicroMed Technology, Inc., Houston, Texas) axial flow pump is presently in clinical trials in Europe as a bridge to transplant in patients with end-stage heart failure. The miniaturized pump is an implantable, titanium, electromagnetically actuated axial flow pump. The purpose of the pump is to provide mechanical assistance to the failing left ventricle, thereby improving and maintaining end organ function. The goal of the entire system is to provide safe, reliable ventricular support while allowing the recipient to maintain a good quality of life. Methods: The DeBakey VAD(TM) has been implanted in 13 patients. Support has ranged from 9-115 days. Hemodynamic evaluations along with blood chemistry analysis were routinely recorded. Exercise tolerance was observed. Results: End organ function after implant has either shown improvement or remained stable at baseline. Patients have been able to perform normal low level activity and have tolerated position changes without difficulty or evidence of postural hemodynamic changes. Select patients have taken supervised out-of-hospital excursions. Conclusions: Hemodynamic evaluations indicate that the DeBakey VAD(TM) may be applied in patients with end-stage heart failure to provide mechanical assistance to the failing left ventricle. Blood chemistry analysis and clinical observations indicate the application of the DeBakey VAD(TM) aids in improving and maintaining end organ function. After recovery from surgery and the effects of heart failure, patients with the DeBakey VAD(TM) are able to perform the basic activities of daily living.",
keywords = "Axial flow pump, Bridge to transplant, Heart failure, Ventricular assist device",
author = "Noon, {G. P.} and R. Hetzer and Matthias Loebe and E. Wolner and G. Wieselthaler and H. Schima and Fabiani, {J. N.} and N. D'Attellis and DeBakey, {M. E.}",
year = "2000",
language = "English (US)",
volume = "5",
pages = "30--32",
journal = "Cardiovascular Engineering",
issn = "1432-9077",
publisher = "Pabst Science Publishers",
number = "1",

}

TY - JOUR

T1 - Clinical experience with the DeBakey VAD(TM) axial flow pump

AU - Noon, G. P.

AU - Hetzer, R.

AU - Loebe, Matthias

AU - Wolner, E.

AU - Wieselthaler, G.

AU - Schima, H.

AU - Fabiani, J. N.

AU - D'Attellis, N.

AU - DeBakey, M. E.

PY - 2000

Y1 - 2000

N2 - Background: The DeBakey VAD(TM) (MicroMed Technology, Inc., Houston, Texas) axial flow pump is presently in clinical trials in Europe as a bridge to transplant in patients with end-stage heart failure. The miniaturized pump is an implantable, titanium, electromagnetically actuated axial flow pump. The purpose of the pump is to provide mechanical assistance to the failing left ventricle, thereby improving and maintaining end organ function. The goal of the entire system is to provide safe, reliable ventricular support while allowing the recipient to maintain a good quality of life. Methods: The DeBakey VAD(TM) has been implanted in 13 patients. Support has ranged from 9-115 days. Hemodynamic evaluations along with blood chemistry analysis were routinely recorded. Exercise tolerance was observed. Results: End organ function after implant has either shown improvement or remained stable at baseline. Patients have been able to perform normal low level activity and have tolerated position changes without difficulty or evidence of postural hemodynamic changes. Select patients have taken supervised out-of-hospital excursions. Conclusions: Hemodynamic evaluations indicate that the DeBakey VAD(TM) may be applied in patients with end-stage heart failure to provide mechanical assistance to the failing left ventricle. Blood chemistry analysis and clinical observations indicate the application of the DeBakey VAD(TM) aids in improving and maintaining end organ function. After recovery from surgery and the effects of heart failure, patients with the DeBakey VAD(TM) are able to perform the basic activities of daily living.

AB - Background: The DeBakey VAD(TM) (MicroMed Technology, Inc., Houston, Texas) axial flow pump is presently in clinical trials in Europe as a bridge to transplant in patients with end-stage heart failure. The miniaturized pump is an implantable, titanium, electromagnetically actuated axial flow pump. The purpose of the pump is to provide mechanical assistance to the failing left ventricle, thereby improving and maintaining end organ function. The goal of the entire system is to provide safe, reliable ventricular support while allowing the recipient to maintain a good quality of life. Methods: The DeBakey VAD(TM) has been implanted in 13 patients. Support has ranged from 9-115 days. Hemodynamic evaluations along with blood chemistry analysis were routinely recorded. Exercise tolerance was observed. Results: End organ function after implant has either shown improvement or remained stable at baseline. Patients have been able to perform normal low level activity and have tolerated position changes without difficulty or evidence of postural hemodynamic changes. Select patients have taken supervised out-of-hospital excursions. Conclusions: Hemodynamic evaluations indicate that the DeBakey VAD(TM) may be applied in patients with end-stage heart failure to provide mechanical assistance to the failing left ventricle. Blood chemistry analysis and clinical observations indicate the application of the DeBakey VAD(TM) aids in improving and maintaining end organ function. After recovery from surgery and the effects of heart failure, patients with the DeBakey VAD(TM) are able to perform the basic activities of daily living.

KW - Axial flow pump

KW - Bridge to transplant

KW - Heart failure

KW - Ventricular assist device

UR - http://www.scopus.com/inward/record.url?scp=0034077725&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034077725&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0034077725

VL - 5

SP - 30

EP - 32

JO - Cardiovascular Engineering

JF - Cardiovascular Engineering

SN - 1432-9077

IS - 1

ER -